Literature DB >> 18237847

Is CA 19-9 useful in the management of pancreatic cancer?

Gianpaolo Balzano, Valerio Di Carlo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18237847     DOI： 10.1016/S1470-2045(08)70011-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Study on chronic pancreatitis and pancreatic cancer using MRS and pancreatic juice samples.

Authors:  Jian Wang; Chao Ma; Zhuan Liao; Bing Tian; Jian-Ping Lu
Journal:  World J Gastroenterol       Date:  2011-04-28       Impact factor: 5.742

2.  Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/mL.

Authors:  Jin-Feng Xiang; Wen-Quan Wang; Liang Liu; Hua-Xiang Xu; Chun-Tao Wu; Jing-Xuan Yang; Zi-Hao Qi; Ya-Qi Wang; Jin Xu; Chen Liu; Jiang Long; Quan-Xing Ni; Min Li; Xian-Jun Yu
Journal:  Sci Rep       Date:  2016-01-12       Impact factor: 4.379

3.  A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer.

Authors:  Yuntao Chen; Zhenyi Shao; Wen Chen; Hua Xie; Zhenyu Wu; Guoyou Qin; Naiqing Zhao
Journal:  Oncotarget       Date:  2017-05-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.